New Ray Medicine International Holding (HKSE:06108) Change In Working Capital : HK$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Change In Working Capital?

New Ray Medicine International Holding's change in working capital for the quarter that ended in Dec. 2023 was HK$0.00 Mil.

New Ray Medicine International Holding's change in working capital for the fiscal year that ended in Dec. 2023 was HK$-37.77 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

New Ray Medicine International Holding Change In Working Capital Historical Data

The historical data trend for New Ray Medicine International Holding's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Change In Working Capital Chart

New Ray Medicine International Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-38.34

-33.13

-69.90

15.83

-37.77

New Ray Medicine International Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

New Ray Medicine International Holding Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

New Ray Medicine International Holding Change In Working Capital Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

New Ray Medicine International Holding (HKSE:06108) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN

Website

http://www.newraymedicine.com

New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.

Executives

Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping	2201 Interest of corporation controlled by you
Qian Shenglei	2101 Beneficial owner
Zhang Jiang	2201 Interest of corporation controlled by you
Yang Fang	2202 Interest of your spouse
Zhou Ling	2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines